Literature DB >> 8384210

A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA.

M M McLaughlin1, L B Cieslinski, M Burman, T J Torphy, G P Livi.   

Abstract

We have isolated cDNA clones from human frontal cortex cDNA libraries that encode a unique subtype of the low-Km, cAMP-specific phosphodiesterases (PDEs IV). The 564-amino acid sequence of the protein (human brain PDE IV (hPDE IVB)) shows significant homology to a PDE IV subtype expressed in human monocytes (hPDE IVA), particularly within the approximately 300-amino acid PDE IV catalytic domain. The degree of protein sequence identity is much greater between hPDE IVB and a homolog derived from rat brain (92% over 562 amino acids) than between hPDE IVB and hPDE IVA (76% over 538 amino acids), suggesting a greater subtype-specific versus species-specific conservation of protein sequence. Analysis of the distribution of hPDE IVB mRNA expression revealed a restricted pattern, with an approximately 4-kilobase mRNA detected in brain, heart, lung, and skeletal muscle and not in placenta, liver, kidney, or pancreas. An additional approximately 5-kilobase hPDE IVB-related mRNA species was detected in brain tissue. Recombinant hPDE IVB displayed all of the expected kinetic characteristics for a PDE IV, including sensitivity to the isozyme-selective inhibitor rolipram (Ki = 0.085 microM). Scatchard analysis of (R)-[3H]rolipram binding data suggested the presence of two noninteracting high affinity rolipram-binding sites (Kd = 0.4 and 6 nM) or a negatively cooperative interaction among multiple binding sites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384210

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Authors:  E Huston; S Lumb; A Russell; C Catterall; A H Ross; M R Steele; G B Bolger; M J Perry; R J Owens; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

3.  Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.

Authors:  G B Bolger; S Erdogan; R E Jones; K Loughney; G Scotland; R Hoffmann; I Wilkinson; C Farrell; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

4.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Authors:  J E Souness; C Maslen; S Webber; M Foster; D Raeburn; M N Palfreyman; M J Ashton; J A Karlsson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

5.  The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

Authors:  B Hughes; D Howat; H Lisle; M Holbrook; T James; N Gozzard; K Blease; P Hughes; R Kingaby; G Warrellow; R Alexander; J Head; E Boyd; M Eaton; M Perry; M Wales; B Smith; R Owens; C Catterall; S Lumb; A Russell; R Allen; M Merriman; D Bloxham; G Higgs
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 6.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

7.  Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.

Authors:  Sergey Udalov; Rio Dumitrascu; Soni S Pullamsetti; Hamza M Al-tamari; Norbert Weissmann; Hossein A Ghofrani; Andreas Guenther; Robert Voswinckel; Werner Seeger; Friedrich Grimminger; Ralph T Schermuly
Journal:  BMC Pulm Med       Date:  2010-05-05       Impact factor: 3.317

8.  Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.

Authors:  L Sekut; D Yarnall; S A Stimpson; L S Noel; R Bateman-Fite; R L Clark; M F Brackeen; J A Menius; K M Connolly
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

9.  Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions.

Authors:  M Lobban; Y Shakur; J Beattie; M D Houslay
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.